KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q3 2025 value amounting to $54.0 million.

  • Vertex Pharmaceuticals' Depreciation & Amortization (CF) rose 150.38% to $54.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $200.6 million, marking a year-over-year decrease of 869.37%. This contributed to the annual value of $207.2 million for FY2024, which is 1428.57% up from last year.
  • Vertex Pharmaceuticals' Depreciation & Amortization (CF) amounted to $54.0 million in Q3 2025, which was up 150.38% from $51.7 million recorded in Q2 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Depreciation & Amortization (CF) peaked at $59.0 million during Q4 2023, and registered a low of $28.8 million during Q1 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' median Depreciation & Amortization (CF) value was $41.4 million (recorded in 2023), while the average stood at $43.0 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Depreciation & Amortization (CF) surged by 5364.58% in 2023, and later tumbled by 2118.64% in 2024.
  • Vertex Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $33.8 million in 2021, then increased by 13.61% to $38.4 million in 2022, then skyrocketed by 53.65% to $59.0 million in 2023, then fell by 21.19% to $46.5 million in 2024, then rose by 16.13% to $54.0 million in 2025.
  • Its Depreciation & Amortization (CF) stands at $54.0 million for Q3 2025, versus $51.7 million for Q2 2025 and $48.4 million for Q1 2025.